PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-No auction for Vectura as Carlyle declares $1.3 bln takeover bid final

Tue, 10th Aug 2021 17:02

(Recasts, adds detail, background)

By Yadarisa Shabong

Aug 10 (Reuters) - The takeover battle between tobacco giant
Philip Morris and private equity firm Carlyle for
inhaled treatments maker Vectura will not be heading to
the auction ring on Wednesday after Carlyle said it will not
raise its bid.

U.S.-based Carlyle on Tuesday declared final its 155 pence
per Vectura share offer, which it sweetened last week to value
the British company at about 958 million pounds ($1.33 billion).
The proposal is below an increased 165 pence bid from Philip
Morris on Sunday.

Britain's takeover regulator on Monday had intervened in the
battle, saying that it would enter a rare head-to-head auction https://www.reuters.com/world/uk/britains-takeover-regulator-intervenes-battle-drugmaker-vectura-2021-08-09
if the bidders do not make final bids by Tuesday 1600 GMT (1700
BST).

Only a handful of British takeover fights have gone to
auction, with the highest profile in recent years being the
battle in 2018 for pay-television group Sky when Comcast
emerged as the winner of a single-day three round
blind auction.

London-listed shares of Vectura closed at 163.4 pence on
Tuesday after hitting a more than five-year high of 176 pence
earlier in the session. They have gained 33% in value since
Carlyle's first offer in May.

Vectura has been the target of several approaches since May
from the U.S.-based groups, which are eyeing the drugmaker's
expertise with inhalable formulations and device designs for
respiratory therapies for illnesses such as asthma.

The London-listed company had voiced its support for the
Carlyle offer last week, saying that it may be better positioned
under the ownership of the private equity firm, while noting the
uncertainties that could arise for its stakeholders as a result
of being owned by the Marlboro cigarette-maker.

However, Vectura withdrew its backing and also withheld
support for the higher offer from Philip Morris following the
intervention from the Takeover Panel.

Vectura did not immediately respond to a request for
comment.

A deal with either one of the U.S. companies would require
shareholder approval.
($1 = 0.7229 pounds)

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Shounak
Dasgupta and Lisa Shumaker)

More News
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more
4 Dec 2020 13:05

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

Read more
30 Nov 2020 09:53

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Read more
30 Nov 2020 08:06

Vectura signs asthma treatment deal with Kinaset

(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.

Read more
20 Nov 2020 08:34

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

Read more
19 Nov 2020 20:25

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
15 Sep 2020 17:22

Vectura Revenue Slips But Swings To First Half Profit

Vectura Revenue Slips But Swings To First Half Profit

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
2 Sep 2020 19:36

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

Read more
7 Jul 2020 16:35

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

Read more
9 Jun 2020 12:04

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

Read more
8 Jun 2020 15:00

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.